Safety and efficacy of durvalumab with R-CHOP or R2-CHOP in untreated, high-risk DLBCL: a phase 2, open-label trial

Grzegorz S. Nowakowski, Wolfgang Willenbacher, Richard Greil, Thomas Stauffer Larsen, Krish Patel, Ulrich Jäger, Robert Manges, Lorenz Trümper, Hele Everaus, Nagesh Kalakonda, Peter de Nully Brown, Judit Jørgensen, David Cunningham, Justine Dell’Aringa, Brian A. Fox, Neus Domper Rubio, Nurgul Kilavuz, Marie‐Laure Casadebaig, Oliver Manzke, Javier Muñoz